Aceto Announces Fiscal 2012 Third Quarter Results of Operations
FISCAL 2012 THIRD QUARTER HIGHLIGHTS (Comparisons to FY 2011 3Q):
PORT WASHINGTON, N.Y., May 3, 2012 (GLOBE NEWSWIRE) -- Aceto Corporation (Nasdaq:ACET), a global leader in the marketing, sales and distribution of pharmaceutical active ingredients and intermediates, finished dosage form generic pharmaceuticals, nutraceutical products, agricultural protection products and specialty chemicals today announced results of operations for its fiscal 2012 third quarter and nine months ended March 31, 2012.
Commenting on the results, Albert Eilender, Chairman and CEO of Aceto, stated, "We are very pleased with our fiscal 2012 third quarter results, with all of our business segments performing at or above our expectations. Sales in our Health Sciences segment were up 10.5% compared to last year, largely driven by new products launched in fiscal 2012. As previously announced, Rising Pharmaceuticals launched two new generics in the fiscal third quarter, for a total of six new products in the fiscal year to date. Our product pipeline remains strong and we are well positioned for continued growth in this business."
"Sales in our Specialty Chemicals segment increased 8.9% in the fiscal third quarter, partially due to continued demand for agricultural intermediates, dye, pigment and miscellaneous industrial additives in our domestic operations. Agricultural Protection sales declined, as expected, due to the planned phase out of glyphosate sales. Additionally, drought conditions in the Southern U.S. resulted in fewer orders for certain agricultural protection products. Looking forward, we remain optimistic about our long-term growth prospects; however, we continue to expect sales fluctuations on a quarterly basis due to the nature of our sales cycle and the markets we serve," Mr. Eilender concluded.
Net sales for the fiscal 2012 third quarter were $121.4 million, an increase of 3.0% from $117.9 million reported in the fiscal 2011 third quarter. Gross profit increased 14.0% to $22.2 million in the 2012 fiscal third quarter, compared to $19.4 million in the 2011 fiscal third quarter. Net income increased 39.9% to $5.4 million, or $0.20 per diluted share, for the 2012 fiscal third quarter, compared to net income of $3.8 million, or $0.14 per diluted share, for the comparable quarter of fiscal 2011. Net income and earnings per share for the fiscal 2012 third quarter included a benefit of $0.5 million, or $0.02 per share, respectively due to a favorable tax adjustment.
Net sales for the nine months ended March 31, 2012 were $333.4 million, a 14.5% increase from $291.2 million for the comparable period in fiscal 2011. Gross profit for the first nine months of fiscal 2012 was $61.3 million, an increase of 33.8% from $45.8 million in the first nine months of fiscal 2011. For the first nine months of fiscal 2012, the Company reported net income of $13.0 million, or $0.49 per diluted share, compared to $5.5 million, or $0.21 per diluted share in comparable period of fiscal 2011. The fiscal 2012 period was negatively impacted by a one-time charge relating to the separation of certain executive management employees, while the fiscal 2011 period was impacted by two one-time charges relating to the December 31, 2010 acquisition of assets of Rising Pharmaceuticals, Inc. After adjusting for the one-time charges in both periods and a favorable tax adjustment in the first nine months of fiscal 2012, Aceto's net income was $13.0 million, or $0.49 per diluted share, for the first nine months of fiscal 2012, compared to $8.8 million, or $0.34 per diluted share, for the 2011 comparable period.
Albert Eilender, Salvatore Guccione, Ronald Gold and Douglas Roth will conduct a conference call at 9:00 a.m. ET on Friday, May 4, 2012 to discuss the operating results for the fiscal 2012 third quarter. Interested parties may participate in the call by dialing 800-446-2782 (847-413-3235 for international callers) – please call in 10 minutes before the call is scheduled to begin, and ask for the Aceto call (conference ID # 32291731). The conference call will also be webcast live via the Investor Relations section of our website, www.aceto.com. To listen to the live call please go to the website at least 15 minutes early to register, download and install any necessary audio software. The conference call will be archived on the Company's website, and a recorded phone replay will also be available from 1:00 p.m. ET on Friday May 4, 2012 until 5:00 p.m. ET on Monday May 7, 2012. Dial 888-843-7419 (630-652-3042 for international callers) and enter the code 32291731 for the phone replay.
Aceto Corporation, incorporated in 1947, is a global leader in the marketing, sales and distribution of pharmaceutical active ingredients and intermediates, finished dosage form generic pharmaceuticals, nutraceutical products, agricultural protection products and specialty chemicals. With business operations in nine countries, Aceto distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries. Aceto's global operations, including a staff of 26 in China and 12 in India are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities. (ACET-F)
FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements as that term is defined in the federal securities laws. The events described in forward-looking statements contained in this news release may not occur. Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of Aceto's plans or strategies, financing plans, projected or anticipated benefits from acquisitions that Aceto may make, or projections involving anticipated revenues, earnings or other aspects of Aceto's operating results or financial position, and the outcome of any contingencies. Any such forward-looking statements are based on current expectations, estimates and projections of management. Aceto intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained in this press release include, but are not limited to, statements regarding the Company's strategic initiatives including selling finished dosage form generic drugs, and statements regarding the prospects for long-term growth. Aceto cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond Aceto's control, which may influence the accuracy of the statements and the projections upon which the statements are based. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in Aceto's reports filed with the Securities and Exchange Commission, including, but not limited to, Aceto's Annual Report or Form 10-K for the fiscal year ended June 30, 2011 and other filings. Copies of these filings are available at www.sec.gov.
Any one or more of these uncertainties, risks and other influences could materially affect Aceto's results of operations and whether forward-looking statements made by Aceto ultimately prove to be accurate. Aceto's actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements. Aceto undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.
CONTACT: Investor Relations Contact: Amy Glynn The Ruth Group (646) 536-7023 email@example.com
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here